XML 36 R24.htm IDEA: XBRL DOCUMENT
v3.25.2

INVESTMENT IN EQUITY SECURITIES | 6 Months Ended
--- | ---
Jun. 30, 2025
Equity Method Investments and Joint Ventures [Abstract] |
INVESTMENT IN EQUITY SECURITIES | INVESTMENT IN EQUITY SECURITIES Our investment in equity securities consisted of the following:
| June 30, 2025 |  | December 31, 2024
Equity Method Investments: |  |  |
Goldrain | $ | 99,862 |  |  | $ | 96,667 |
BTY | 33,505 |  |  | 32,047 |
Sonmol | 6,490 |  |  | 4,712 |
Desotec GmbH | 1,135 |  |  | 948 |
Other Investments: |  |  |
PureCycle | 3,992 |  |  | 2,986 |
YAT | 5,304 |  |  | 5,206 |
Loop | 2,894 |  |  | 2,894 |
Others | 919 |  |  | 809 |
| $ | 154,101 |  |  | $ | 146,269 |
Equity Method Investments Goldrain On October 22, 2024, we acquired 40% of the equity interests in Ningbo Jinyu Technology Industry Co., Ltd., doing business as Goldrain, (referred to as “Goldrain”), a leading manufacturer of dispensing technologies in China for an approximate purchase price of $99 million. Goldrain is a leading manufacturer specialized in developing and producing packages for skin care, cosmetic, household, cleaning, personal care and perfumery products. BTY On January 1, 2020, we acquired 49% of the equity interests in three related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”) for an approximate purchase price of $32.0 million. We have a call option to acquire an additional 26% to 31% of BTY’s equity interests following the initial lock-up period of 5 years based on a predetermined formula. Subsequent to the second lock-up period, which ends 3 years after the initial lock-up period, we have a call option to acquire the remaining equity interests of BTY based on a predetermined formula. Additionally, the selling shareholders of BTY have a put option for the remaining equity interest to be acquired by Aptar based on a predetermined formula. The BTY entities are leading Chinese manufacturers of high quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry. For the six months ended June 30, 2025 and June 30, 2024, we had purchases of $5.6 million and $5.8 million, respectively, from BTY. As of June 30, 2025 and December 31, 2024, approximately $2.2 million and $2.5 million, respectively, was due to BTY and included in accounts payable, accrued and other liabilities on our Condensed Consolidated Balance Sheets. On June 12, 2025, we signed an Equity Transfer Agreement with the selling shareholders to exercise our call option to acquire an additional 31% of BTY's equity interests for an estimated purchase price of $36 million. The transaction closed on July 28, 2025, subject to customary closing conditions. As a result of this acquisition, we anticipate a remeasurement of our previously held minority equity interest in BTY at fair value resulting in a non-cash gain of approximately $23 million during the third quarter of 2025. Due to the timing of the acquisition, the initial purchase accounting is not yet complete and will be included in the third quarter Form 10-Q filing. The business will be consolidated into our Beauty segment during the third quarter Form 10-Q filing. Sonmol On April 1, 2020, we invested $5.0 million to acquire 30% of the equity interests in Healthcare, Inc., Shanghai Sonmol Internet Technology Co., Ltd. and its subsidiary, Shanghai Sonmol Medical Equipment Co., Ltd. (collectively referred to as “Sonmol”). Sonmol is a leading Chinese pharmaceutical company that provides consumer electric devices and connected devices for asthma control. Desotec GmbH During 2009, we invested €574 thousand to acquire 23% of the equity interests in Desotec GmbH, a leading manufacturer of specialty assembly machines for bulk processing for the pharmaceutical, beauty and closures markets. Other Investments In prior years, we invested, through a series of transactions, an aggregate amount of $2.9 million in preferred equity investments in Loop, a sustainability company. In prior years, we also invested, through a series of transactions, $3.0 million in PureCycle and received $0.7 million of equity in exchange for our resource dedication for technological partnership and support. In March 2021, PureCycle became a publicly-traded company and listed its common stock on Nasdaq under the ticker symbol “PCT,” At that time, our investment in PureCycle was converted into shares of common stock of PCT resulting in less than a 1% ownership interest. This investment is now recorded at fair value based on observable market prices for identical assets and the change in fair value is recorded as a net investment gain or loss in the Condensed Consolidated Statements of Income. No shares were sold during 2024 or 2025 related to PCT. On April 26, 2024, we received $0.2 million of equity in exchange for our resource dedication for technological partnership and support. For the three and six months ended June 30, 2025 and 2024, we recorded the following net investment gain or loss on our investment in PureCycle:
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Net investment gain (loss) | $ | 2,102 |  |  | $ | (140) |  |  | $ | 1,006 |  |  | $ | 452 |
On July 7, 2021, we investe d approximately $5.9 million to acquire 10% of the equity interests in YAT, a multi-functional, science-driven online skincare solutions company. There were no indications of impairment noted in the six months ended June 30, 2025 and 2024 related to these investments.

X
- Definition The entire disclosure for equity method and other investments. + References No definition available. + Details
Name: | atr_EquityMethodAndOtherInvestmentsTextBlock
Namespace Prefix: | atr_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration